FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387567510> ?p ?o ?g. }

• W4387567510 abstract "Hand osteoarthritis is a disabling condition with few effective therapies. Hand osteoarthritis with synovitis is a common inflammatory phenotype associated with pain. We aimed to examine the efficacy and safety of methotrexate at 6 months in participants with hand osteoarthritis and synovitis.In this multisite, parallel-group, double-blind, randomised, placebo-controlled trial, participants (aged 40-75 years) with hand osteoarthritis (Kellgren and Lawrence grade ≥2 in at least one joint) and MRI-detected synovitis of grade 1 or more were recruited from the community in Melbourne, Hobart, Adelaide, and Perth, Australia. Participants were randomly assigned (1:1) using block randomisation, stratified by study site and self-reported sex, to receive methotrexate 20 mg or identical placebo orally once weekly for 6 months. The primary outcome was pain reduction (measured with a 100 mm visual analogue scale; VAS) in the study hand at 6 months assessed in the intention-to-treat population. Safety outcomes were assessed in all randomly assigned participants. This trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12617000877381).Between Nov 22, 2017, and Nov 8, 2021, of 202 participants who were assessed for eligibility, 97 (48%) were randomly assigned to receive methotrexate (n=50) or placebo (n=47). 68 (70%) of 97 participants were female and 29 (30%) were male. 42 (84%) of 50 participants in the methotrexate group and 40 (85%) of 47 in the placebo group provided primary outcome data. The mean change in VAS pain at 6 months was -15·2 mm (SD 24·0) in the methotrexate group and -7·7 mm (25·3) in the placebo group, with a mean between-group difference of -9·9 (95% CI -19·3 to -0·6; p=0·037) and an effect size (standardised mean difference) of 0·45 (0·03 to 0·87). Adverse events occurred in 31 (62%) of 50 participants in the methotrexate group and 28 (60%) of 47 participants in the placebo group.Treatment of hand osteoarthritis and synovitis with 20 mg methotrexate for 6 months had a moderate but potentially clinically meaningful effect on reducing pain, providing proof of concept that methotrexate might have a role in the management of hand osteoarthritis with an inflammatory phenotype.National Health and Medical Research Council of Australia." @default.
• W4387567510 created "2023-10-13" @default.
• W4387567510 creator A5001397633 @default.
• W4387567510 creator A5007693688 @default.
• W4387567510 creator A5008416988 @default.
• W4387567510 creator A5026779492 @default.
• W4387567510 creator A5035218732 @default.
• W4387567510 creator A5037141982 @default.
• W4387567510 creator A5038612232 @default.
• W4387567510 creator A5047388413 @default.
• W4387567510 creator A5067870302 @default.
• W4387567510 creator A5071553641 @default.
• W4387567510 date "2023-10-01" @default.
• W4387567510 modified "2023-10-17" @default.
• W4387567510 title "Methotrexate to treat hand osteoarthritis with synovitis (METHODS): an Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial" @default.
• W4387567510 cites W1937062091 @default.
• W4387567510 cites W1963910487 @default.
• W4387567510 cites W1980807679 @default.
• W4387567510 cites W1985004174 @default.
• W4387567510 cites W1987181501 @default.
• W4387567510 cites W2026123588 @default.
• W4387567510 cites W2032541700 @default.
• W4387567510 cites W2040105893 @default.
• W4387567510 cites W2070705145 @default.
• W4387567510 cites W2094586574 @default.
• W4387567510 cites W2122435770 @default.
• W4387567510 cites W2132562166 @default.
• W4387567510 cites W2137674910 @default.
• W4387567510 cites W2148997013 @default.
• W4387567510 cites W2157771298 @default.
• W4387567510 cites W2157919456 @default.
• W4387567510 cites W2161739351 @default.
• W4387567510 cites W2170823733 @default.
• W4387567510 cites W2597733778 @default.
• W4387567510 cites W2888824226 @default.
• W4387567510 cites W2895008287 @default.
• W4387567510 cites W2897749763 @default.
• W4387567510 cites W2902669954 @default.
• W4387567510 cites W3159389642 @default.
• W4387567510 cites W3213141748 @default.
• W4387567510 cites W4211142475 @default.
• W4387567510 cites W4231972505 @default.
• W4387567510 cites W4233138142 @default.
• W4387567510 cites W4321495345 @default.
• W4387567510 doi "https://doi.org/10.1016/s0140-6736(23)01572-6" @default.
• W4387567510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37839420" @default.
• W4387567510 hasPublicationYear "2023" @default.
• W4387567510 type Work @default.
• W4387567510 citedByCount "1" @default.
• W4387567510 crossrefType "journal-article" @default.
• W4387567510 hasAuthorship W4387567510A5001397633 @default.
• W4387567510 hasAuthorship W4387567510A5007693688 @default.
• W4387567510 hasAuthorship W4387567510A5008416988 @default.
• W4387567510 hasAuthorship W4387567510A5026779492 @default.
• W4387567510 hasAuthorship W4387567510A5035218732 @default.
• W4387567510 hasAuthorship W4387567510A5037141982 @default.
• W4387567510 hasAuthorship W4387567510A5038612232 @default.
• W4387567510 hasAuthorship W4387567510A5047388413 @default.
• W4387567510 hasAuthorship W4387567510A5067870302 @default.
• W4387567510 hasAuthorship W4387567510A5071553641 @default.
• W4387567510 hasConcept C126322002 @default.
• W4387567510 hasConcept C141071460 @default.
• W4387567510 hasConcept C14184104 @default.
• W4387567510 hasConcept C142724271 @default.
• W4387567510 hasConcept C156957248 @default.
• W4387567510 hasConcept C168563851 @default.
• W4387567510 hasConcept C1862650 @default.
• W4387567510 hasConcept C202061045 @default.
• W4387567510 hasConcept C204787440 @default.
• W4387567510 hasConcept C27081682 @default.
• W4387567510 hasConcept C2776164576 @default.
• W4387567510 hasConcept C2777077863 @default.
• W4387567510 hasConcept C2779244835 @default.
• W4387567510 hasConcept C2908647359 @default.
• W4387567510 hasConcept C2991744798 @default.
• W4387567510 hasConcept C535046627 @default.
• W4387567510 hasConcept C71924100 @default.
• W4387567510 hasConcept C99454951 @default.
• W4387567510 hasConceptScore W4387567510C126322002 @default.
• W4387567510 hasConceptScore W4387567510C141071460 @default.
• W4387567510 hasConceptScore W4387567510C14184104 @default.
• W4387567510 hasConceptScore W4387567510C142724271 @default.
• W4387567510 hasConceptScore W4387567510C156957248 @default.
• W4387567510 hasConceptScore W4387567510C168563851 @default.
• W4387567510 hasConceptScore W4387567510C1862650 @default.
• W4387567510 hasConceptScore W4387567510C202061045 @default.
• W4387567510 hasConceptScore W4387567510C204787440 @default.
• W4387567510 hasConceptScore W4387567510C27081682 @default.
• W4387567510 hasConceptScore W4387567510C2776164576 @default.
• W4387567510 hasConceptScore W4387567510C2777077863 @default.
• W4387567510 hasConceptScore W4387567510C2779244835 @default.
• W4387567510 hasConceptScore W4387567510C2908647359 @default.
• W4387567510 hasConceptScore W4387567510C2991744798 @default.
• W4387567510 hasConceptScore W4387567510C535046627 @default.
• W4387567510 hasConceptScore W4387567510C71924100 @default.
• W4387567510 hasConceptScore W4387567510C99454951 @default.
• W4387567510 hasLocation W43875675101 @default.
• W4387567510 hasLocation W43875675102 @default.
• W4387567510 hasOpenAccess W4387567510 @default.
• W4387567510 hasPrimaryLocation W43875675101 @default.

• next